重组人血管内皮抑制素联合SP方案治疗晚期胃癌的效果观察  

Recombinant human endostatin combined with SP regimen for advanced gastric cancer

作　　者：杨景茹[1] 苏飞 令晓玲[1] 赵达[1] YANG Jingru;SU Fei;LING Xiaoling;ZHAO Da(Department of Oncology,the First Hospital of Lanzhou University,Lanzhou 730000,China)

机构地区：[1]兰州大学第一医院肿瘤内科,兰州730000

出　　处：《中华实用诊断与治疗杂志》2020年第7期735-738,共4页Journal of Chinese Practical Diagnosis and Therapy

基　　金：甘肃卫生行业科研计划管理项目(WGL2010-20)。

摘　　要：目的探讨晚期胃癌患者应用重组人血管内皮抑制素联合SP(替吉奥+顺铂)方案治疗的疗效及安全性。方法 51例晚期胃癌患者随机分为观察组25例和对照组26例。观察组采用重组人血管内皮抑制素联合SP方案化疗,对照组采用SP方案化疗。化疗2个周期评价缓解率、临床获益率;记录化疗前及化疗2个周期时KPS评分;记录不良反应发生情况;随访观察远期生存情况。结果化疗2个周期时,观察组临床获益率(76.0%)高于对照组(46.2%)(P<0.05),缓解率(40.0%)与对照组(23.1%)比较差异无统计学意义(P>0.05)。观察组、对照组化疗2个周期时KPS评分[(87.20±4.58)、(85.00±5.10)分]均高于化疗前[(65.60±5.83)、(65.38±6.47)分](P<0.05),2组化疗2个周期时KPS评分比较差异无统计学意义(P>0.05)。化疗2个周期时,2组不良反应发生率比较差异无统计学意义(P>0.05)。观察组中位无进展生存期(7.7个月)、中位总生存期(14.9个月)与对照组(6.2、13.8个月)比较差异无统计学意义(P>0.05)。结论晚期胃癌患者应用重组人血管内皮抑制素联合SP方案治疗可提高近期疗效,改善机体功能状态,且不增加不良反应,但对远期疗效无明显改善。Objective To investigate the efficacy and safety of recombinant human endostatin combined with SP regimen(S-1/Tegafur)for advanced gastric cancer.Methods Fifty-one patients with advanced gastric cancer were randomly divided into observation group(n=25)receiving recombinant human endostatin combined with SP chemotherapy and control group(n=26)receiving SP chemotherapy.The response rate and clinical benefit rate were evaluated after two cycles of chemotherapy.KPS scores were recorded before and after two cycles of chemotherapy.The adverse reactions during chemotherapy were recorded and the long-term survival was followed up.Results After two cycles of chemotherapy,the clinical benefit rate was higher in observation group(76.0%)than that in control group(46.2%)(P<0.05),and the response rate showed no significant difference between observation group(40.0%)and control group(23.1%)(P>0.05).The KPS scores were higher in observation group and control group after 2 cycles of chemotherapy(87.20±4.58,85.00±5.10)than those before chemotherapy(65.60±5.83,65.38±6.47)(P<0.05),and showed no significant difference between two groups after chemotherapy(P>0.05).There were no significant differences in the incidence of adverse reactions after 2 cycles of chemotherapy between two groups(P>0.05),as well as in the median progress-free survival(7.7 months vs.6.2 months)and the median overall survival(14.9 months vs.13.8 months)between observation group and control group(P>0.05).Conclusion Recombinant human endostatin combined with SP can improve the short-term efficacy,improve the functional status of patients,and does not increase the adverse reactions,but it has no obvious long-term efficacy on advanced gastric cancer.

关 键 词：晚期胃癌 替吉奥胶囊 顺铂 重组人血管内皮抑制素 

分 类 号：R735.2[医药卫生—肿瘤]